REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/27/2026
Back to search
Official data from USPTO
DEVATIS, INC.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
07/27/2026
Trademark type
Combined
Nice classes
5
Filing date
08/26/2020
Registration date
07/27/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/27/2021
Last transaction
07/27/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
09
Owner location
TR
Examiner
LAVACHE, LINDA M
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "DEVATIS, INC." in dark blue font, except for the letter "D" that appears in light blue. The wording appears inside a black single-line square carrier. The color white represents background and/or transparent areas only and is not part of the mark.
Holders and representatives
Holders
DEVA HOLDING ANONIM SIRKETI
Representatives
Nicholas D. Wells Legends Law Group, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in treating by inhibiting the growth of tumorsas antiparasiticsfor treatment of the nervous systemsorthopedic and musculoskeletal diseaserespiratory diseasegenital and urologic diseaseendocrinology diseasecardiovascular diseasedermatological diseasemetabolic diseasegastrointestinal diseasehormonal diseasesophthalmological diseasecancer and diseases of the bloodfor use in treating immune functionpsychiatric disordersfatiguesexual disfunction; veterinary preparations for use in treating by inhibiting the growth of tumorsas antiparasiticsfor treatment of the nervous systemsorthopedic and musculoskeletal diseaserespiratory diseasegenital and urologic diseaseendocrinology diseasecardiovascular diseasedermatological diseasemetabolic diseasegastrointestinal diseasehormonal diseasesophthalmological diseasecancer and diseases of the bloodfor use in treating immune functionpsychiatric disordersfatiguesexual disfunction; sanitary preparations for medical purposes; dietetic foodsfood supplements and dietary supplements adapted for medical use; dietetic sugar for medical use; food for babies; dietary supplements for humans and animals; medical plasters; material for stopping teethdental wax; all-purpose disinfectants; preparations for destroying vermin; fungicidesherbicides
Publications
History of USPTO decisions and trademark events.
31 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/26/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/23/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/29/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
12/22/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
12/22/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/27/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/27/2021
GPNX
NOTIFICATION PROCESSED BY IB
05/17/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/11/2021
PUBO
PUBLISHED FOR OPPOSITION
05/11/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/26/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/21/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/21/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/05/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
04/05/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/05/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
04/05/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/05/2021
RFNT
REFUSAL PROCESSED BY IB
03/22/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/15/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/15/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/15/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/03/2021
RFRR
REFUSAL PROCESSED BY MPU
03/02/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/26/2021
CNRT
NON-FINAL ACTION WRITTEN
02/25/2021
MAFR
APPLICATION FILING RECEIPT MAILED
02/23/2021
DOCK
ASSIGNED TO EXAMINER
02/19/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/19/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/18/2021
Continuous trademark protection
Get notified about every new filing that threatens DEVATIS, INC. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.